Whitehawk Therapeutics/$WHWK
1D1W1MYTD1Y5YMAX
Capital at risk
About Whitehawk Therapeutics
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
- Ticker
- $WHWK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 32
- Headquarters
- Morristown, United States
- Website
- ir.whitehawktx.com
WHWK Metrics
BasicAdvanced
$232M
-
-$1.10
0.78
-
Price and volume
Market cap
$232M
Beta
0.78
52-week high
$5.50
52-week low
$1.80
Average daily volume
343K
Financial strength
Current ratio
17.383
Quick ratio
17.163
Profitability
EBITDA (TTM)
-86.056
Management effectiveness
Return on assets (TTM)
-28.70%
Return on equity (TTM)
-44.98%
Valuation
Price to book
1.27
Price to tangible book (TTM)
1.27
Price to free cash flow (TTM)
-4.268
Free cash flow yield (TTM)
-23.43%
Free cash flow per share (TTM)
-0.954
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
328.55%
3-year earnings per share growth (CAGR)
-23.13%
What the Analysts think about WHWK
Analyst ratings (Buy, Hold, Sell) for Whitehawk Therapeutics stock.
Analyst projections of the future price of Whitehawk Therapeutics stock.
WHWK Financial Performance
Revenues and expenses
WHWK Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.